In this episode, Drs. Laura Onderko, Zain Asad, and Aditya Bharadwaj delve into how fellows-in-training and early-career cardiologists can strategically build their research careers and assess whether ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...

The 2025 ACC/AHA Acute Coronary Syndrome (ACS) Guideline clarifies diagnostic distinctions using electrocardiogram changes, troponin levels, and imaging tools such as coronary CT angiography and ...

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

Black Americans suffered nearly 800,000 excess age-adjusted deaths and 24 million excess years of potential life lost due to cardiovascular disease from 2000 to 2022, compared with their White ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

The U.S. Food and Drug Administration (FDA) has approved the EVOQUE tricuspid valve replacement system for the treatment of tricuspid regurgitation (TR). According to an Edwards press release, “it is ...

In this week’s View, Dr. Eagle looks at major trials presented at the recent ESC Congress in Spain. First, he discusses the MAPLE-HCM trial that investigates aficamten versus metoprolol monotherapy in ...

In patients with pre-existing cardiovascular disease and who are overweight or obese, but who do not have diabetes, 2.4 mg of subcutaneous semaglutide taken once weekly was superior to placebo in ...

Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...